Navigation Links
Oral Topical Formulation, ARMS-I, Provides Protection Against Upper Respiratory Infections as well as Reducing Severity and Duration of Cold
Date:2/7/2017

CLEVELAND, Feb. 7, 2017 /PRNewswire/ -- The findings of a randomized proof-of-concept clinical trial demonstrating that the oral spray formulation, ARMS-I, provided protection against upper respiratory tract infections ("URIs") in the enrolled study participants, while reducing the severity and duration of cough and sore throat have just been released.

Funded by ARMS Pharmaceutical, the double-blinded, placebo-controlled trial was conducted by University Hospital's Cleveland Medical Center's Division of Infectious Diseases and Case Western Reserve University. The conclusion of the study states, "ARMS-I is safe and well-tolerated, and it reduces influenza symptoms. This product has the potential to prevent viral upper respiratory tract infections."

Chief Scientific Officer of ARMS Pharmaceutical, Dr. Mahmoud Ghannoum said, "The results confirm that our ARMS-I technology has tremendous potential to lead the next generation of drugs in not only the prevention of many upper respiratory infectious diseases, such as influenza, rhinovirus and respiratory syncytial virus, but in the treatment of them as well." 

ARMS-I is a patented formulation, comprising a broad-spectrum antimicrobial agent (cetylpyridinium chloride, "CPC") and components (glycerin and xanthan gum) that form a barrier on the host mucosa, thus preventing viral contact with the host cells and invasion. 

The U.S. Food and Drug Administration ("FDA") has accepted the company's Investigational New Drug Application ("IND") for a pharmacokinetic trial of its ARMS-I drug, as the company continues to study and develop the use of ARMS-I for its first indication as a potential drug for the prevention of influenza.

"It is an exciting time for the company as we actively begin discussions with potential strategic partners to bring ARMS-I to market, a drug with the potential to help millions of people prevent influenza without the worries of side effects or viral resistance," added Afif Ghannoum, Chief Executive Officer of ARMS Pharmaceutical.

About ARMS Pharmaceutical LLC
ARMS Pharmaceutical LLC, a clinical stage pharmaceutical company, was founded in 2013. The company focuses on the R&D of its ARMS technology platform. ARMS-I is the company's lead drug candidate for the prevention of influenza. Through strategic partnerships, ARMS Pharmaceutical plans to commercialize its ARMS platform for the prevention and treatment of various infectious diseases.

Media Contact:
BLAZE PR / Matt Kovacs
mkovacs@blazepr.com
310-395-5050

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oral-topical-formulation-arms-i-provides-protection-against-upper-respiratory-infections-as-well-as-reducing-severity-and-duration-of-cold-300402975.html


'/>"/>
SOURCE ARMS Pharmaceutical LLC
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. BioPharmX Data Suggest Anti-Inflammatory Activity of BPX-01 Topical Minocycline Gel
2. Otsuka Licenses Pre-Phase 3 Topical Atopic Dermatitis Treatment to Medimetriks
3. Encore Vision, Inc. Announces Completion of Target Enrollment in Clinical Study Evaluating Topical EV06 for the Treatment of Presbyopia
4. Study Shows Topical BioPharmX Formulation Treats Acne While Minimizing Systemic Exposure of Minocycline
5. Snapshot of Innovations in R&D Targeting Key Applications of Drug Delivery Technologies - Oral Route, Pulmonary, Topical, Implantable, Injectable, Transdermal & Transmucosal Route Analysis
6. Immune Pharmaceuticals Announces New Data with Topical Cyclosporine Nano-Capsules in Dermatology
7. Teligent, Inc. Announces Submission of Two Topical ANDAs
8. Global Topical Drug Delivery Partnering 2010-2015
9. Study Shows Safety of BioPharmX Topical Formulation
10. Allergan Enters Into Licensing Agreement with Mimetogen Pharmaceuticals to Develop and Commercialize Tavilermide (MIM-D3) Topical Dry Eye Treatment
11. Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... 4, 2017  According to the Centers for Disease Control and Prevention ... . PhysicianOne Urgent Care is helping communities across Massachusetts ... , by offering no-cost* flu shots through the end of the month. ... health insurance regulations. ... to get a flu shot is by the end of October, according ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, the ... by Walgreens and pharmacy benefit manager Prime Therapeutics LLC ... brand, which included the unveiling of new signage at ... as well as at a few other company-owned facilities ... brand to patients, some of whom will begin to ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... 12, 2017 , ... The American College of Medical Informatics (ACMI) will present ... the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... Collen, a pioneer in the field of medical informatics, this prestigious award is presented ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards luncheon ... editorial and design excellence across a range of sectors. This year’s program included the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... nation's first interactive health literacy software tool, and the Cancer Patient Education Network ... cancer patient education, today announce a new strategic alliance. , As CPEN’s ...
Breaking Medicine News(10 mins):